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The 17th ISCHS took place in Osaka, Japan, on 23 to 25 September 2013. This symposium focuses on an exchange
of views on the structure and function of hepatic sinusoidal cells in addition to their roles in clinical
pathophysiology.
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The 17th International Symposium on Cells of the Hepatic
Sinusoid (ISCHS) took place at the Osaka International
Convention Center in Nakanoshima, Osaka, Japan, 23 to
25 September 2013. The 17th ISCHS was organized to-
gether with the 27th Annual Meeting of Hepatic Sinusoidal
Research Japan (HSRJ) and the 20th Annual Meeting of the
Japanese Society of the Research of Hepatic Cells as part of
Japan Liver Cell Week 2013. In total, 191 scientists from 15
nations attended the 17th ISCHS. The ISCHS originates
from the International Kupffer Cell Symposium organized
by Professors Eddie Wisse and Dick L Knock on 4 to 7
September 1977 in Noordwijkerhout, The Netherlands.
The 17th ISCHS was the third meeting of the International
Society for Hepatic Sinusoidal Research (ISHSR), which
was founded in 2008. The first ISHSR meeting (15th
ISCHS), organized by Professor Hidekazu Tsukamoto, was
held in Pasadena, California, USA in 2010, while the second
meeting (16th ISCHS), held in Florence, Italy in 2011, was
organized by Professor Massimo Pinzani. Professor Kyuichi
Tanikawa founded the HSRJ in 1987, and the first HSRJ
meeting was held in Kurume, Japan on 14 December 1987.
Subsequent annual meetings have been organized at several
locations in Japan.
The opening lecture of the 17th ISCHS was given by
Kyuichi Tanikawa (Professor Emeritus, Kurume MedicalCorrespondence: kawadanori@gmail.com
Department of Hepatology, Graduate School of Medicine, Osaka City
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stated.University, Fukuoka, Japan). He discussed his research
(representing more than 30 years) and displayed photo-
graphs of himself with Professors Eddie Wisse and Hans
Popper to show his interaction with the international com-
munity. He emphasized the importance of studying the
ultrastructure of hepatic sinusoidal cells, particularly with
respect to the liver fibrosis and portal hypertension fields.
Following the opening lecture, the scientific sessions of
the 17th ISCHS began. The meeting was divided into five
thematic sessions: (1) stellate cell and liver fibrosis 1 and 2;
(2) inflammation and immunity 1 and 2; (3) cutting edge
lecture on hepatic sinusoidal endothelial cells; (4) cancer
microenvironment 1 and 2; and (5) alcoholic steatohepati-
tis (ASH) and non-alcoholic steatohepatitis (NASH) 1 and
2. In addition to oral presentations at the seminars, seven
tutorial talks, five invited talks, four keynote lectures, one
cutting edge lecture, three communication talks, and 20
selected oral presentations were presented thematically. Of
the 44 posters presented, seven were selected for oral pres-
entation in the ‘President-selected Short Oral Presentation
of Poster’ session.
This meeting was sponsored by the ISHSR and cospon-
sored by the National Institute on Alcohol Abuse and
Alcoholism (NIAAA)/National Institute of Health (NIH),
The Southern California Research Center for ALPD &
Cirrhosis, Distilled Spirits Council of the United States
(DISCUS), and The Uehara Memorial Foundation. This
meeting was also supported by industry and the affili-
ate hospitals of the Department of Hepatology, OsakaThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Seminars
In this symposium, two morning seminars, four luncheon
seminars, and one evening seminar were planned. These
seminars offered information on general and current
topics in clinical and basic hepatology, such as hepatitis
virus C (HCV), non-alcoholic steatohepatitis (NASH), the
diagnosis and treatment of liver fibrosis and cirrhosis, and
acute liver failure with a focus on the biology of sinusoidal
and other liver cells.
John Peter Iredale (University of Edinburgh, Edinburgh,
UK) gave Morning Seminar I, ‘Matrix, myofibroblasts and
macrophages: players in bidirectional fibrosis’. He empha-
sized that the hepatic scar is dynamic with respect to both
its cellular and matrix components. The resolution of liver
fibrosis, even in relatively advanced cirrhosis, occurs co-
operatively: activated stellate cell-derived myofibroblasts
that abundantly express tissue inhibitor of matrix metallo-
proteinase (Timp 1) mRNA act in conjunction with mac-
rophages, which are critical in matrix degradation due to
their production of matrix metalloproteinases (Mmps) 12
and 13. Restorative macrophages, such as Ly-6Cint macro-
phages, are larger and more complex than pro-fibrotic
macrophages. Interaction between macrophages and liver
stem cells through TWEAK, Wnt, and Notch should be
taken into account.
Takaji Wakita (National Institute of Infectious Disease,
Tokyo, Japan) led Morning Seminar II, ‘Hepatitis C virus
cell culture system and antiviral development’. He is a
pioneer in establishing cell culture models of HCV repli-
cation and infection. In addition to introducing his ana-
lyses of the viral life cycle and his efforts to establish an
anti-viral vaccine strategy, he reported that glycyrrhizin,
a compound derived from licorice root that is frequently
used for treating chronic hepatitis C in Japan, has an in-
hibitory effect on phospholipase A2 group 1B that pre-
vents the release of infectious HCV particles. Moreover,
he noted that HCV entry into stellate cells modulates
the activation of these cells.
Four Luncheon Seminars were presented. Massimo
Pinzani (University College London-Royal Free Hospital,
London, UK) gave the talk ‘How our knowledge on liver
fibrogenesis can improve the clinical management of
chronic liver disease’. He mentioned that advances in
the development of non-invasive and repetitive quantifi-
cation of liver fibrosis can be attributed to progress in
serum fibrosis markers and ultrasound-based transient
elastography rather than the classical biopsy-based semi-
quantitative scoring system of liver fibrosis. Additionally,
he stated that in the near future, modern imaging tech-
nology will permit the tracking of receptors and signal-
ing molecules involved in the fibrotic process. He alsoemphasized that cirrhosis is a dynamic clinical stage that
should be classified subdivided into several stages to
understand its fundamental reversibility and to develop
therapeutic strategies.
Satoshi Mochida (Saitama Medical University, Saitama,
Japan) gave the talk ‘Acute liver failure in Japan-definition,
classification and prediction of the outcome’. Acute liver
failure is caused by massive hepatocyte necrosis. This con-
dition occurs in patients infected with hepatitis virus A or
B, autoimmune hepatitis or certain other diseases, and is
accompanied by blood coagulation disequilibrium in the
hepatic sinusoid. Although the pathogenesis of acute liver
failure remains to be clarified, the Intractable Hepato-
Biliary Disease Study Group of Japan reported diagnostic
criteria for this disease and a scoring system to predict pa-
tient outcome in 2011. Therapeutic strategies other than
liver transplantation for this rare but lethal liver disease
should be established based on the outcome of cell-based
mechanical analyses.
Gyongyi Szabo (University of Massachusetts Medical
School, Worcester, MA, USA) presented ‘Inflammation
and danger signals in alcoholic and non-alcoholic fatty
liver disease’. Her lecture on the pathogenesis of ALD
and NAFLD focused on endogenous and exogenous dan-
ger signals. Innate signaling molecules and pathways, such
as toll-like receptors (Tlrs) and inflammasomes, contrib-
ute to inflammation in ALD and NAFLD. Activation of
the Nlr family, pyrin domain containing 3 (Nlrp3) inflam-
masome, and caspase-1/interleukin 1β (Il-1β) is involved
in the pathogenesis of ALD.
Kazuaki Chayama (Hiroshima University, Hiroshima,
Japan) presented ‘Studies on hepatitis viruses using human
hepatocyte chimeric mice’. He utilized human hepatocyte
chimeric mice to study HBV and HCV virology. Human
hepatocytes were transplanted into albumin enhancer/
promoter-driven urokinase plasminogen activator/severe
combined immunodeficient (uPA/SCID) mice to generate
the first human hepatocyte chimeric mice. This innovative
mouse model has utility for both anti-viral drug screening
and analyses of viral dynamics. He commented on the
current status of their group’s studies using this mouse
model to explore the life cycles of HBV and HCV and to
develop new anti-viral therapeutic strategies.
Takehiro Okabayashi (Kochi Health Science Center,
Kochi, Japan) gave the talk ‘Perioperative nutritional man-
agement using branched chain amino acid (BCAA) in
hepatic resection patients’ at Evening Seminar I. BCAA
supplements are used therapeutically to improve the nutri-
tional status and quality of life of patients with end-stage
liver disease and cirrhosis. Recent studies have revealed
that BCAA can prevent cirrhosis-related complications
and prolong the survival of cirrhotic patients by suppress-
ing the occurrence of hepatocellular carcinoma (HCC);
however, a detailed molecular mechanism is lacking. In this
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plementation supports hepatocyte proliferation by stimu-
lating the migration of extrahepatic stem cells from the
bone marrow into the site of liver damage.
Stellate cells and fibrosis
This session was composed of three tutorial talks, four
invited talks, and five oral presentations selected from
submitted abstracts. Tutorial Talk 1 was given by Kenjiro
Wake (Professor Emeritus, Tokyo Medical and Dental
University/Minophagen Pharmaceutical Co. Ltd., Tokyo,
Japan) who contributed to the ‘re’ discovery and confirm-
ation of the presence of hepatic stellate cells in the space
of Disse. Using microscopy and electron microscopy tech-
nologies, he determined that these stellate cells contain
lipid droplets of vitamin A within their cytoplasms. Fur-
thermore, the 3D structure of these stellate cells, revealed
both by Golgi’s silver staining method and by a cell culture
model, suggested that they are liver-specific pericytes that
regulate sinusoidal microcirculation via their contractile
ability. He also described the heterogeneity of these stel-
late cells and their interactions with neighboring hepato-
cytes and endothelial cells.
Kinji Asahina (University of Southern California, Los
Angeles, CA, USA) gave a talk on the role of mesothelial
cells in liver fibrosis. Conditional cell lineage tracing re-
vealed that mesothelial cells are able to transdifferentiate
into hepatic stellate cells, fibroblasts, and smooth muscle
cells during liver development. Mesothelial-mesenchymal
transition occurs in response to transforming growth fac-
tor β (Tgf-β) stimulation and gives rise to hepatic stellate
cells and myofibroblasts, thereby suggesting that these
cells contribute to the capsular fibrosis of the chronically
damaged liver. Based on this report, myofibroblasts may
be derived from at least three different sources in the liver:
hepatic stellate cells, portal myofibroblasts, and mesothe-
lial cells.
Chantal Housset (Saint-Antonie Research Center, Paris,
France) discussed myofibroblast sub-populations in the
liver. She mentioned that myofibroblasts in the liver
originate from hepatic stellate cells and portal/periportal
myofibroblasts. However, there are some differences
between the two cell types; portal myofibroblasts play
dominant roles in scar formation, while hepatic stellate
cell-derived myofibroblasts are important in the heal-
ing process. These two cell populations have different
functions during hepatic vascular remodeling.
Eva Moran’s (University of Barcelona, Barcelona,
Spain) presentation on cell-specific peroxisome proliferator-
activated receptor γ (Pparγ) deficiency using the Cre-LoxP
gene targeting system revealed anti-inflammatory and anti-
fibrogenic properties for this nuclear receptor in non-
parenchymal liver cells. Mice with macrophage-specific
deletion of Pparγ (Pparγf/-LysM-Cre) showed markednecroinflammatory injury and lipid peroxidation, an aug-
mented fibrogenic response to chronic carbon tetrachloride
(CCl4) intoxication, activation of caspase 3 and caspase 3/7,
and increased expression of cyclooxygenase 2 (Cox-2),
tumor necrosis factor α (Tnfα), and Il-1. Identical results
were obtained by the specific deletion of Pparγ in stellate
cells (Pparγf/-aP2-Cre). She concluded that Pparγ expres-
sion in non-parenchymal liver cells is protective against in-
flammation and fibrosis in liver injury.
Takeshi Saito (University of Southern California, Los
Angeles, CA, USA) gave a talk on the retinoid regulation
of hepatic antiviral innate immunity. He showed that al-
cohol dehydrogenase (Adh) expression in a cell line
enhances retinoic acid (RA) production in hepatocytes,
resulting in the enhanced expression of interferon-
stimulated gene (Isg) and the potentiation of the anti-
viral action of interferon (Ifn) in the induction of Isg.
Thus, vitamin A-rich, quiescent stellate cells supply ret-
inols to hepatocytes, thereby facilitating their antiviral
innate immunity.
Yoon Seok Noh (University of California, San Diego,
La Jolla, CA, USA) showed that the Tlr7-type 1 Ifn sig-
naling axis inhibits cholestasis- and hepatotoxin-induced
liver fibrosis through the induction of Il-1 receptor an-
tagonists. Using both KO mice and a cell culture model,
he demonstrated that Tlr7 signaling induces dendritic
cells to produce type I Ifn (α and β). Secreted type I Ifn
triggers the production of an Il-1 receptor antagonist by
Kupffer cells. Finally, this Il-1 receptor antagonist regu-
lates the bile duct ligation-induced liver fibrosis process.
These results elucidate the detailed molecular mechanism
by which clinically utilized type I Ifn represses fibrosis.
Hidekazu Tsukamoto (Keck School of Medicine of the
University of South California, Los Angeles, CA, USA)
gave Tutorial Talk 2 in this session. He commented on
facts and wonders of hepatic stellate cells. He emphasized
that Pparγ is a key gene regulating the differentiation or
quiescence of stellate cells. Its epigenetic repression, medi-
ated by morphogens such as Wnt, Shh, Necdin, and Dlk1,
induces a myofibroblastic cell fate. He also discussed the
role of stellate cells in hepatic oncogenesis.
Sophie Lotersztajn (Hospital Henri Mondor, Creteil,
France) gave Tutorial Talk 3 on cannabinoid receptors
as antifibrogenic targets during chronic liver disease.
CB1 receptor antagonists display beneficial effects on
lipid metabolism and have anti-fibrotic properties. The
CB2 receptor is a promising antifibrotic target that has
indirect anti-inflammatory effects on Kupffer cells and
Th17 lymphocytes.
Yasuko Iwakiri (Yale University School of Medicine,
New Haven, CT, USA) gave Invited Talk 3. The talk fo-
cused on Nogo-B (Reticulon 4B), a novel regulator of
liver fibrosis and portal hypertension. Nogo-B belongs
to the reticulon family of proteins and is present in the
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ture and protein trafficking. Using Nogo-B deficient mice,
she demonstrated that Nogo-B attenuates liver fibrosis by
disturbing the Tgf-β/Smad2 pathway and inducing apop-
tosis of activated stellate cells. Nogo-B is also involved in
the development of portal hypertension.
Klaas Poelstra (University of Groningen, Groningen,
The Netherlands) gave Invited Talk 4. He discussed
maneuvering cytokines to modulate fibrogenesis. When
truncated, Ifn γ acts as a mimetic by binding the platelet-
derive growth factor (Pdgf) receptor instead of its own
receptor, thereby inducing significant antifibrotic effects.
In contrast, pegylated Il-10, which has potent antifibrotic
effects, exhibits significant pro-fibrotic effects when deliv-
ered to the Pdgf receptor in vivo. Thus, the cell-specific
delivery of cytokines to hepatic sinusoidal cells modulates
disease activity.
Yutaka Furutani (Riken Center for Life Science
Technologies, Saitama, Japan) gave a selected oral presen-
tation on reduced angiogenesis and fibrosis in the liver of
transglutaminase 2-deficient mice after bile duct ligation.
Transglutaminase 2-deficient mice injected with VEGF
display a 50% reduction in angiogenesis and liver fibrosis
compared to wild-type mice, indicating that transglutami-
nase 2 is involved in Tgf-β activation. The latent form of
Tgf-β is produced by neovessels.
Zhimin Zhao (Shanghai University of Traditional Chinese
Medicine, Shanghai, China) gave a talk on the inhibition of
liver fibrosis and angiogenesis in vivo and in vitro by levisti-
lide A. Levistilide A is derived from the herb Angelica
Sinensis (Danggui) and has been used to treat liver disease
in China. This compound caused reduced expression of
von Willebrand factor and attenuated CCl4-induced liver
fibrosis and sinusoidal capillarization.
Communications on ‘Fibrosis in extrahepatic organs’
Communications on ‘Fibrosis in extrahepatic organs’
was first programmed in ISCHS. It has been well estab-
lished that fibroblast-like cells similar to hepatic stellate
cells and myofibroblasts reside not only in the liver but
also in the pancreas, kidney, lung, gut, spleen, and other
visceral organs. Recent studies have demonstrated that
these stellate cells in extrahepatic organs, some of which
are specialized to store vitamin A, play a myriad of roles
in the development of fibrosis within individual organs.
In this session, the molecular and cellular basis of fibro-
sis in the lung, kidney, and pancreas were discussed in
this context.
Thomas A Wynn (National Institute of Allergy and
Infectious Disease, NIH, Bethesda, MD, USA) gave a talk
on the roles of Tgf-β1, Il-13, and inflammatory mediators
in mouse models of pulmonary fibrosis. He mentioned
that pulmonary fibrosis induced by chronic allergen
exposure is Il-13 dependent, while bleomycin-inducedfibrosis is mediated by Il-17A produced by CD4+ T cells
and γδ+T cells. Pulmonary fibrosis is suppressed by Il-10
and augmented by Ifn γ and Il-12/23p40. Thus, he con-
cluded that both Il-13 and Il-17A are important mediators
of pulmonary fibrosis.
Motoko Yanagita (Kyoto University, Kyoto, Japan)
gave a talk on the origin and function of scar-forming
cells in the kidney. Although epithelial-mesenchymal
transition (EMT) takes part in some myofibroblasts in the
fibrotic kidney, the trans-differentiation of erythropoietin-
expressing, neural crest-derived fibroblasts into Pdgf β- and
αSma-positive myofibroblasts is dominantly involved.
Selective estrogen receptor modulators such as tamoxi-
fen can reverse this process. She also emphasized that
epithelial-fibroblast interactions trigger fibroblast dys-
function during kidney injury.
Astushi Masamune (Tohoku University, Sendai, Japan)
gave a talk on the role of pancreatic stellate cells in pan-
creatic fibrosis. There are vitamin A-positive, periacinar,
stellate-shaped cells in both the human and rodent pan-
creas. Like hepatic stellate cells, pancreatic stellate cells
undergo trans-differentiation from a quiescent pheno-
type to an αSma-positive and ECM-producing activated
phenotype. In addition to exhibiting profibroblastic char-
acteristics, pancreatic stellate cells are involved in insulin
secretion by β-cells and in the resistance of cancer cells
to chemotherapy and radiotherapy.
Inflammation and immunity
This session was composed of two tutorial talks and five
oral presentations selected from submitted abstracts.
Laura Nagy (Cleveland Clinic, Cleveland, OH, USA) gave
Tutorial Talk 4. She discussed the role of complement in
alcoholic and non-alcoholic liver disease. She described
data from several types of KO mice to demonstrate that
ethanol feeding induces the activation of the complement
cascade, which, in turn, stimulates sinusoidal Kupffer cells
to produce Tnf-α, thereby triggering hepatocyte damage.
C1q and the classical complement pathway are critical
mediators of both ASH and NAFLD.
Following the tutorial talk, Maria Lauda Tomasi (Keck
School of Medicine of the University of South California,
Los Angeles, CA, USA) gave a talk on the molecular
mechanism of lipopolysaccharide (LPS)-mediated inhib-
ition of glutathione synthesis in murine macrophages.
LPS lowers the expression of glutamate-cysteine ligase
by mediating decreased sumoylation of nuclear factor
erythroid 2-related factor 2 (Nrf2) and MafG. LPS treat-
ment reduced the co-occupancy of Nrf2 and MafG on
the same promoter region containing the antioxidant
response element. This report showed that the LPS-
mediated downregulation of protein sumoylation is in-
volved in the expression of antioxidant defense system
genes.
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gave a talk on the role of the chemokine receptor (Ccr)
6 in the pathogenesis of chronic and acute-on-chronic
liver disease. Ccr6−/− mice showed augmented expres-
sion of both pro-inflammatory (monocyte chemotactic
protein (Mcp)-1, Icam-1, and Il-6) and pro-fibrogenic
(collagen 1a1 (Col1a1) and Tgf-β) mRNAs in response
to liver injury. She also observed the increased recruit-
ment of an altered CD4+ and CD4+Foxp3+ dendritic cell
population that led to the exacerbation of liver inflam-
mation and fibrogenic reactions in Ccr6−/− mice.
Hartmut Jaeschke (University of Kansas Medical Center,
Kansas City, KS, USA) gave the second tutorial talk in this
session (Tutorial Talk 5). Acetaminophen (APAP) is one
of the most commonly used drugs worldwide and occa-
sionally induces fatal acute liver failure (400–500 deaths/
year in the US). An intermediate metabolite of APAP,
NAPQI, induces necrosis in hepatocytes; however, the
innate immune response to this process remains to be
clarified. He demonstrated that APAP-induced liver dam-
age is not augmented by exogenous Il-1β and occurs in Il-1
receptor-, caspase 1-, and Nalp3-deficient mice, indicating
that the activation of the Nalp3 inflammasome has no rele-
vant impact on APAP hepatotoxicity in mice. Infiltrating
macrophages are critical for the recovery phase of APAP-
induced liver injury.
Yoshihiro Kamada (Osaka University, Osaka, Japan) gave
a talk on the effect of N-acetylglucosaminyltransferase V
(GnT-V) on the progression of chronic hepatitis with stea-
tosis. GnT-V catalyzes beta 1–6 branching in asparagine-
linked oligosaccharides. The expression of a GnT-V
transgene under control of the beta-actin promoter pre-
vents inflammatory and fibrogenic reactions in mice fed
a high-fat, high-cholesterol diet. Although hepatic stellate
cells isolated from GnT-V transgenic mice expressed high
levels of Tgf-β1 mRNA, they expressed lower levels of
collagen 1a1 compared to stellate cells isolated from wild-
type mice. This discrepancy can be explained by the
overexpression of cyclooxygenase-2 and the resultant
overproduction of prostaglandin E2, which negatively reg-
ulates collagen 1a1 mRNA expression in stellate cells iso-
lated from GnT-V transgenic mice.
Ayako Mabuchi (University of Otago, Dunedin, New
Zealand) gave a talk on the role of Tlr4 in stellate cell
activation and hepatocyte proliferation during liver re-
generation. Partial hepatectomies (70%) were performed
in wild-type mice, Tlr4 deficient mice, and mice treated
with MTS510 (a rat anti-mouse Tlr4/Md2 monoclonal
antibody). After hepatectomy, DNA synthesis in hepato-
cytes was comparable among the groups, while an in-
crease in ALT was limited in to Tlr4-deficient mice and
mice treated with MTS510. Three days after PH, the
livers of Tlr4-deficient mice showed an incomplete re-
generative process: NF-κB activation was not present,and αSma-positive activated stellate cells were undetect-
able. Accordingly, she concluded that stellate cell activa-
tion, but not hepatocyte proliferation, is Tlr-dependent
during liver regeneration.
Andrej Khandoga (University of Munich, Munich,
Germany) gave a talk on the interactions between hep-
atic stellate cells and T cells during hepatic ischemia-
reperfusion (I/R) injury in mice. T cell-hepatic stellate
cell interactions were visualized in vivo after the infusion
of fluorescein-labeled CD4+ T cells into Cx3CR1 mice
harboring GFP-labeled stellate cells. The results demon-
strated that co-localization of CD4+ T cells and stellate
cells was evident after I/R and was attenuated by
JWH133, a CB-2 agonist. ACPA, a CB-1 agonist, had no
effect. In addition, JWH133 treatment significantly at-
tenuated I/R-dependent hepatocyte damage, indicating
that a selective depletion/deactivation of stellate cells
reduces T cell-dependent I/R injury.
Cutting edge lecture on sinusoidal endothelial cells
Laurie DeLeve (Keck School of the University of Southern
California, Los Angeles, CA, USA) reviewed the topic of
liver sinusoidal endothelial cells in liver regeneration. Liver
sinusoidal cell progenitor cells (SPCs) are composed of
resident (intrahepatic) SPCs and bone marrow SPCs (BM
SPCs). BM SPCs are required for the repair of liver sinus-
oidal endothelial cells (LSECs) after both toxic injury and
partial hepatectomy and accumulate in the liver in re-
sponse to hepatic Vegf. Stromal cell-derived factor 1 acts
downstream of Vegf to regulate BM SPC recruitment and
engraftment. BM SPCs are the major source of hepatocyte
growth factor (Hgf) and promote hepatocyte proliferation,
while resident SPCs are presumed to play a role in normal
LSEC turnover.
Cancer microenvironment
This session was composed of three keynote lectures,
one invited talk, and four oral presentations selected
from the submitted abstracts. In previous ISCHS sympo-
sia, the anatomical and histological features of hepatic
sinusoidal cells and their involvement in the fibrotic re-
action, local inflammation and immunity, and sinusoidal
microcirculation have been principally discussed. Re-
cently, more clinically relevant roles of sinusoidal cells
have also been discussed. The session entitled ‘Cancer
Microenvironment’ outlined current trends.
Ekihiko Seki (University of California, San Diego, La
Jolla, CA, USA) gave keynote lecture 1. He is interested in
liver fibrosis and liver cancer development. Mice deficient
in transforming growth factor (Tgf)-β-activated kinase 1
(Tak1) in hepatocytes (Tak1ΔHep) showed spontaneous de-
velopment of liver cancer accompanied with hepatocyte
death (increased ALT) and marked fibrosis. TakΔHep livers
showed marked activation of the Smad 2/3 pathway.
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hepatocytes obviously reduced the number of tumors de-
veloped and the extent of fibrosis, indicating that Tgfβ-sig-
naling is a prerequisite for liver cancer development in
TakΔHep mice. Further analyses revealed the contribution
of Smad 4 in hepatocytes during cancer development in
TakΔHep mice. In the last part of his talk, he further em-
phasized the importance of Tgf-β signaling in hepato-
cyte cell death and lipid accumulation in a mouse model
of NASH.
Shin Maeda (Yokohama City University, Yokohama,
Japan) gave keynote lecture 2. E-cadherin (Cdh) is an
important cell-cell adhesion molecule that generates ad-
herence junctions; however, its role in tumor develop-
ment remains controversial. Both hepatocyte-specific
Cdh-deficient mice (CdhΔL) and bile duct epithelial-
specific Cdh-deficient mice developed fibro-inflammatory
lesions around bile ducts without displaying obvious de-
rangement in bile duct epithelial cell morphology. CdhΔL
mice exhibited augmented expression of Sox9, Cd44, and
K19 around bile ducts and developed spontaneous liver
tumors in some cases. The Kras and ERK signaling cas-
cades mediated this process. Furthermore, he explained
that the knockdown of Cdh in Hep3B cancer cells upregu-
lated EMT and the expression of stem cell markers such
as Cd44. He concluded that E-cadherin is a true tumor
suppressor in the liver.
Eiji Hara (Japanese Foundation for Cancer Research,
Tokyo, Japan) gave keynote lecture 3. Obesity is a risk
factor for developing cancer, although the mechanism
connecting these two pathologic conditions remains un-
determined. He reported that the involvement of cellular
senescence and senescence-associated secretary pheno-
types (SASPs) in tumor formation is caused by obesity,
using mice fed a high-fat diet (HFD) and given DMBA, a
compound that induces H-ras mutations. Interestingly,
he determined that senescent cells in HFD-fed mouse
livers are hepatic stellate cells expressing p21, p16, γH2AX,
and αSma. The depletion of senescent hepatic stellate cells
using si-heat shock protein 47 decreased tumor develop-
ment. Taken together, these data demonstrate that HFD-
induced SASPs in stellate cells are a prerequisite for cancer
development in this model. Furthermore, he demonstrated
that deoxycholic acid (DCA), a gut bacterial metabolite,
contributes to the induction of senescence in stellate cells.
The gram-positive bacteria Clostridium Cluster XI princi-
pally produce DCA in the gut.
Fernando Vidal-Vanaclocha (CEU-San Pablo University,
Madrid, Spain) gave Invited talk 5. This talk described the
mechanism of colon cancer cell metastasis to the liver.
Colon cancer induces the production of factors required
for ‘liver prometastatic reaction’ by creating a special
microenvironment supporting the colonization of hepatic
sinusoidal cells by metastatic cancer cells. Il-1β, Il-1βconverting enzyme, or Ddr2 deficiency have a similar
microenvironment that promotes liver prometastatic re-
action. He further described microenvironment-related
genes whose expression levels were regulated by hepato-
cytes, hepatic myofibroblasts or both, as well as genes
representative of the liver prometastatic reaction.
Hayato Hikita (Osaka University, Osaka, Japan) reported
that liver carcinogenesis is induced by continuous apop-
tosis and oxidative stress in hepatocytes. Continuous
hepatocyte apoptosis was observed in Bcl-xL or Mcl-1-de-
ficient mice. More than 88% of these mice develop liver
cancer within 1.5 years compared to 0% of wild-type mice.
Deep sequencing analyses revealed that mutations in p53
and β-catenin were not involved. However, the methyla-
tion rates of runx3 in both cancerous and non-cancerous
areas were significantly higher in KO mice compared to
wild-type mice. Furthermore, hepatocyte apoptosis was
found to induce oxidative stress accompanied by the
induction of the anti-oxidant enzymes, nqo1 and ho1.
Although N-acetylcysteine treatment has no effect on
inflammation and fibrosis in KO mice, this treatment
markedly decreased the incidence of liver cancer.
Thuy T Le (Osaka City University, Osaka, Japan) pre-
sented a study on liver cancer development in cytoglobin-
deficient mice treated with diethylnitrosamine (DEN) or
choline-deficient amino acid-defined (CDAA) diet. Mice in
both groups exhibited a high incidence of tumor develop-
ment accompanied by significant fibrosis and augmented
oxidative stress. Of note, hepatic stellate cells isolated from
cytoglobin-deficient mice were primed and secreted mul-
tiple cytokines involved in the fibro-inflammatory reaction
in the liver. Because cytoglobin is uniquely expressed in
stellate cells, these findings indicate the direct involvement
of stellate cells in cancer development in the mouse liver.
Hitoshi Yoshiji (Nara Medical University, Nara, Japan)
gave a talk on the effects of combined treatment of sorafe-
nib, a multi kinase inhibitor, and angiotensin II receptor
blocker (ARB) on the development of preneoplastic le-
sions in CDAA-treated rat livers. Both agents are known
to have strong anti-angiogenic activity. Sorafenib (5 mg/
kg/day) showed marked inhibition of the development of
GST-P-positive neoplastic lesions. However, a combined
treatment of ARB, losartan (30 mg/kg/day) and a half dose
of sorafenib (2.5 mg/kg/day) exhibited equivalent anti-
tumor effects, along with hepatic neovascularization and
Vegf expression. Accordingly, he concluded that this regi-
men using a lower dose of sorafenib might provide a new
strategy for treating HCC caused by NASH.
Takuji Torimura (Kurume University School of Medicine,
Fukuoka, Japan) presented the final talk of this session.
He reported anti-tumor effects of aflibercept, a sol-
uble decoy receptor made by fusing VEGF receptors
(VEGFR)-1 and −2 that has the ability to bind both VEGF
and PlGF. Aflibercept suppressed the phosphorylation of
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toma cells, resulting in inhibited cell proliferation. It also
inhibited the differentiation of bone marrow (BM) cells
into endothelial progenitor cells and the migration of BM
cells to tumor tissues. In tumor-bearing mice, aflibercept
reduced the microvascular density and growth of tumor
tissues without serious adverse events.
NASH and ASH
This session was composed of two tutorial talks, one
keynote lecture, and six oral presentations selected from
submitted abstracts. Fabio Marra (University of Florence,
Florence, Italy) gave the first tutorial talk in this session
on the fibrogenic mechanisms in ASH and NASH. Lipo-
toxicity induces hepatocyte dysfunction via apoptosis,
ER stress, oxidative stress, and so on, thereby leading to
stellate cell activation and fibrosis. Ccl2 produced in
adipose tissue plays a role in hepatocyte steatosis, re-
cruitment of inflammatory cells into the liver and oxida-
tive stress. Berberine (BRB), a plant alkaloid with a long
history of medical use, ameliorates MCD-induced stea-
tohepatitis and causes reduced expression of Il-1β, Il-18,
and pannexin-1. In addition, he discussed studies that
used siRNA, the small molecule XMD8-92, and human
cancer tissues to determine the role of ERK5 in HCC
growth.
Ariel Feldstein (University of California, San Diego, La
Jolla, CA, USA) gave keynote lecture 4 on NAFLD, NASH
and cirrhosis. He reported that MCD diet- and CDAA
diet-induced fibrogenic reactions were markedly reduced
in caspase 1- and Tlr2-deficient mice, respectively, indicat-
ing that the Nlrp3 inflammasome participates in NASH.
The group further developed Nlrp3 knock-in mice. These
mice exhibited severe liver inflammation, hepatocyte
pyroptosis, stellate cell activation and collagen depos-
ition, which was at least partially suppressed by an Il-1
receptor antagonist.
Edward N Harris (University of Nebraska, Lincoln, NE,
USA) gave a talk on hepatic sinusoidal endothelial cells
(LSECs) in NAFLD. Rats were fed a high-fat diet (HFD) to
generate fatty livers. No accumulation of lipid was observed
in LSECs, which exhibited nearly intact fenestration, similar
to normal controls. Stabilin 2 mRNA expression was down-
regulated, explaining the increased level of plasma hyaluro-
nan observed in NAFLD.
Mashani Mohamad (University of Sydney, Sydney,
Australia) gave a talk on the defenestration of liver endo-
thelial cells in insulin resistance. F344 rats were treated
with poloxamer 407 (P407), a synthetic surfactant that
causes the defenestration of LSECs and hyperlipidemia.
The multiple indicator dilution method demonstrated
that the hepatic volume of distribution as a fraction of
the extracellular space was significantly decreased for
both insulin and glucose in P407-treated rats. Insulinreceptor substrate 1 protein phosphorylation was also
diminished in the treated rats. These results identify a
role for LSEC structure in insulin resistance.
Kenichi Ikejima (Juntendo University, Tokyo Japan)
gave a talk on the effects of dietary glycine on metabolic
steatohepatitis in diabetic KK-Ay mice. KK-Ay mice fed a
glycine-enriched diet exhibited limited development of
hepatic steatosis and inflammatory infiltration along with
reduced expression of hepatic sterol regulatory element-
binding protein (Srebp)1c, fatty acid synthase, and acetyl
CoA carboxylase. Furthermore, he reported that dietary
glycine significantly increased NKT cell fractions and
mRNA levels of arginase-1, a marker of M2 macrophage
transformation, in KK-Ay mice. He concluded that glycine
is a promising immune-nutrient for the treatment of
NASH.
Jacquelyn J Maher (University of California, San
Francisco, San Francisco, CA, USA) gave tutorial talk 7.
Alcohol and excess nutrients are cellular stressors that
trigger an ‘ER stress’ response that contributes to the
pathogenesis of steatosis and steatohepatitis in ASH,
NASH, and other liver diseases. ER stress generally
causes cell death, inflammation, and fibrosis, which are
mediated by the activation of JNK and CHOP, the latter
of which does not play a central role in the pathogenesis
of MCD-induced steatohepatitis. A recent study indicated
that ER stress is involved in the stellate cell activation
process; thus, ER stress may be a therapeutic target.
Expanding upon this idea, she emphasized the utilization
of bile acids as chemical chaperones with hepatoprotective
properties. Obeticholic acid, a farnesoid X receptor (FXR)
agonist structurally similar to chenodeoxycholic acid, has
demonstrated positive effects in clinical trials for type 2
diabetes and NAFLD.
Akiko Eguchi (University of California, San Diego, La
Jolla, CA, USA) reported the therapeutic efficacy and
safety of suppressing liver Bid using RNA interference or
a Bid inhibitor. Mice were fed a CDAA diet for 19 weeks
to induce NASH. After 3 weeks of treatment with siRNA
and Invivofectamine® Rx, Bid mRNA expression was sup-
pressed by 50%, Bid protein levels were reduced to 10%,
and a marked improvement in liver fibrosis was observed.
Similarly, the administration of a truncated Bid inhibitor
for 4 weeks improved liver fibrosis and suppressed the ex-
pression of hepatic inflammatory genes such as Il-1β, Il-6,
and Tnfα. She concluded that Bid inhibition might be use-
ful as an antifibrotic NASH therapy.
Koichi Miura (Akita University, Akita, Japan) gave a
talk on the role of Tlrs and their downstream effector
molecules in the development of NASH. A CDAA diet
was used to induce NASH in mice. Several lines of gene-
deficient mice were used in this study. The data demon-
strated that both fibrosis and inflammatory reactions
were alleviated in Tlr2−/−, Tlr4 mutant, Tlr9−/−, and
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ered to contribute to the progression of NASH in this
model because they produced cytokines and chemokines
and expressed inflammatory molecules such as Nlrp3,
Nlrp1, Asc, and Aim2. In addition, the CCR2 inhibitor
RS102895, markedly improved NASH.
Tadashi Moro (Tokai University, Isehara, Japan) re-
ported the effects of oxidative stress and high fat intake
on hepatic inflammation and fibrogenesis in Tet-mev-1
mice. He demonstrated that the induction of mitochon-
drial superoxides results in mitochondrial membrane po-
tential in primary hepatocytes and contributes to the
activation of the col1a2 promoter in co-cultured hepatic
stellate cells. In vivo studies showed that doxycycline-
treated Tet-mev-1 mice fed a high fat/high sucrose diet
expressed increased C-C chemokine mRNAs, such as
chemokine ligand 2 (Ccl2), Ccl3, and Ccl4, without ap-
parent fibrosis. This model can be used to evaluate the
direct contribution of mitochondrial oxidative stress to
the progression of liver disease.
Poster session
Forty-four posters were divided into six categories: (1)
Hepatic Stellate Cells, four posters; (2) Liver Fibrosis, 11
posters; (3) Cancer Microenvironment, six posters; (4)
Inflammation and Immunity, 11 posters; (5) NASH, nine
posters; and (6) ASH, three posters. The president se-
lected seven posters from this group, and the authors
were invited to speak at the ‘Short Oral Presentation of
Poster’ session. The presentations included the following:
‘Hepatic stellate cell and biodiversity’ by Haruki Senoo
(Akita University, Akita, Japan); ‘Effect of leptin and etha-
nol on the regulation of apoptosis and fibrosis in the
mouse HCC cell lines’ by Balasubramaniyan Vairappan
(Jawaharlal Institute of Postgraduate Medical Education
and Research, Pondicherry, India); ‘GP130 mediates
inflammation-associated hepatocellular carcinogenesis in
hepatocyte specific Tak-1 deleted mice’ by Yoon Seok Noh
(University of California, San Diego, La Jolla, CA, USA);
‘In vitro liver models: design and cellular interaction
studies’ by Srivastan Kidambi (University of Nebraska-
Lincoln, Lincoln, NE, USA); ‘IFN-γ deficiency attenuates
hepatic inflammation and fibrosis in mouse steatohepatitis’
by Terumi Takahara (Toyama University, Toyama, Japan);
‘Stress accelerates derangement of bile acid homeostasis
during development of steatohepatitis in mice’ by Tsutomu
Matsubara (Osaka City University, Osaka, Japan); and
‘Protein S exacerbates acute alcohol-induced liver injury
by enhancing activation of liver natural killer T cells’ by
Motoh Iwasa (Mie University, Tsu, Japan).
Conclusions
As usual, this symposium focused on discussions of the
structure and function of hepatic sinusoidal cells, includingKupffer cells, sinusoidal endothelial cells, stellate cells, pit
cells, and dendritic cells. However, this Osaka symposium
facilitated the concept of ‘Bridging Basic Science and
Clinical Hepatology’, following the precedent set at the
previous meeting in Florence, Italy, 2011. As progress
accelerates the growth of hepatological science and
medicine, it is necessary to promote the interchange of
knowledge between basic and clinical scientists. To this
end, topics in this symposium included the involvement
of hepatic sinusoidal cells in the pathogenesis of liver fi-
brosis, inflammation and immunological reactions caused
by viral infection, alcohol abuse, and lifestyle-related stea-
tohepatitis, and their applications in the development of
therapeutic regimens for treating liver disease. Sinusoidal
cell involvement in hepatic carcinogenesis was thoroughly
argued. Furthermore, the presentations on the advance-
ment of research on the fibrosis of extrahepatic organs
were outstanding.
The 18th ISCHS symposium will be held in Asilomar,
California, USA in October 2015. Please check the ISHSR
website (http://www.ishsr.net) for further information. See
you in Asilomar in 2015!
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